http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Key Ne19 States Identified Affecting γ -Ray Emission from F18 in Novae
Hall, M. R.,Bardayan, D. W.,Baugher, T.,Lepailleur, A.,Pain, S. D.,Ratkiewicz, A.,Ahn, S.,Allen, J. M.,Anderson, J. T.,Ayangeakaa, A. D.,Blackmon, J. C.,Burcher, S.,Carpenter, M. P.,Cha, S. M.,Chae, K American Physical Society 2019 Physical Review Letters Vol.122 No.5
Applications of Photonuclear Physics for International Safeguards and Security
M. S. Johnson,J. M. Hall,D. P. McNabb,J. L. McFarland,E. B. Norman,W. Bertozzi,S. E. Korbly,R. J. Ledoux,W. H. Park 한국물리학회 2011 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.59 No.23
Studies of nuclear resonance fluorescence based applications are presented. Important for these applications are data for isotopes such as ^(239)Pu. Nuclear resonance fluorescence measurements of ^(239)Pu were performed at the free electron laser facility at UC Santa Barbara using photons from a bremsstrahlung beam with an endpoint energies between 4.0 MeV and 5.5 MeV. Though no discrete states with significant confidence level were measured, we have excluded the region above 27(3) eV-barns, or 4-sigma, where we would expect only a small chance of false positives. Details of the measurements and the results are presented here.
New γ -ray transitions observed in Ne19 with implications for the O15(α,γ)Ne19 reaction rate
Hall, M. R.,Bardayan, D. W.,Baugher, T.,Lepailleur, A.,Pain, S. D.,Ratkiewicz, A.,Ahn, S.,Allen, J. M.,Anderson, J. T.,Ayangeakaa, A. D.,Blackmon, J. C.,Burcher, S.,Carpenter, M. P.,Cha, S. M.,Chae, K American Physical Society 2019 Physical Review C Vol.99 No.3
Tests of a dual-readout fiber calorimeter with SiPM light sensors
Antonello, M.,Caccia, M.,Cascella, M.,Dunser, M.,Ferrari, R.,Franchino, S.,Gaudio, G.,Hall, K.,Hauptman, J.,Jo, H.,Kang, K.,Kim, B.,Lee, S.,Lerner, G.,Pezzotti, L.,Santoro, R.,Vivarelli, I.,Ye, R.,Wig Elsevier 2018 Nuclear Instruments & Methods in Physics Research. Vol.899 No.-
<P><B>Abstract</B></P> <P>In this paper, we describe the first tests of a dual-readout fiber calorimeter in which silicon photomultipliers are used to sense the (scintillation and Čerenkov) light signals. The main challenge in this detector is implementing a design that minimizes the optical crosstalk between the two types of fibers, which are located very close to each other and carry light signals that differ in intensity by about a factor of 60. The experimental data, which were obtained with beams of high-energy electrons and muons as well as in lab tests, illustrate to what extent this challenge was met. The Čerenkov light yield, a limiting factor for the energy resolution of this type of calorimeter, was measured to be about twice that of the previously tested configurations based on photomultiplier tubes. The lateral profiles of electromagnetic showers were measured on a scale of millimeters from the shower axis and significant differences were found between the profiles measured with the scintillating and the Čerenkov fibers.</P>
Keystone, E C,Genovese, M C,Klareskog, L,Hsia, E C,Hall, S T,Miranda, P C,Pazdur, J,Bae, S-C,Palmer, W,Zrubek, J,Wiekowski, M,Visvanathan, S,Wu, Z,Rahman, M U BMJ Publishing Group 2009 Annals of the Rheumatic Diseases Vol.68 No.6
<P><B>Objective:</B></P><P>The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy.</P><P><B>Methods:</B></P><P>Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n = 133), golimumab 100 mg injections plus placebo capsules (group 2, n = 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n = 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n = 89). Injections were administered subcutaneously every 4 weeks. The co-primary endpoints were the proportion of patients with 20% or greater improvement in the American College of Rheumatology criteria (ACR20) at week 14 and the change from baseline in the health assessment questionnaire-disability index (HAQ-DI) score at week 24.</P><P><B>Results:</B></P><P>The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p = 0.059) in the golimumab 100 mg plus placebo group, 55.1% (p = 0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively. During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.</P><P><B>Conclusion:</B></P><P>The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.</P>
Rings and gaps in the disc around Elias 24 revealed by ALMA
Dipierro, G,Ricci, L,Pé,rez, L,Lodato, G,Alexander, R D,Laibe, G,Andrews, S,Carpenter, J M,Chandler, C J,Greaves, J A,Hall, C,Henning, T,Kwon, W,Linz, H,Mundy, L,Sargent, A,Tazzari, M,Testi, L,W Oxford University Press 2018 Monthly notices of the Royal Astronomical Society Vol.475 No.4